Per policy, use of these medications is restricted as noted below:
generic (Brand)
Restrictions
buprenorphine (Subutex, Suboxone)
New starts of buprenorphine for pain or dependence treatment will not be allowed at IHS. Indications for buprenorphine are limited to the following: (1) Continuation of buprenorphine therapy for the maintenance of opioid dependence when the patient is admitted for a medical condition other than opioid addiction. (2) Continuation of chronic pain management if buprenorphine was taken prior to admission. See policy for more details.
Per policy, orders for these non-formulary agents will be changed to formulary equivalents.
Non-Formulary Agent
Formulary Equivalent
buprenorphine (Belbuca) buccal film
Orders must be provided from the patient's home supply. If this supply is not available, the pharmacist will contact the prescriber to discuss alternatives, including conversion to SL buprenorphine tablets.
Enteral Drug Administration notes.
Generic (Brand)
Comments and Considerations
Recommendations for Administration with Enteral Nutrition
buprenorphine (Subutex)
Tablets are intended for SL administration
Consider therapeutic alternative (transdermal, parenteral)
(1) Continuation of buprenorphine therapy for the maintenance of opioid dependence when the patient is admitted for a medical condition other than opioid addiction.
(2) Continuation of chronic pain management if buprenorphine was taken prior to admission.
See policy for more details.
(Brand)
(Subutex)